December 15, 2010 at 09:35 AM EST
FDA to Decide the Fate of AstraZeneca's Heart Drug Brilinta Thursday
More than a year after AstraZeneca filed for approval of its heart drug Brilinta, the FDA will make its decision on Thursday. A large study showed the blood thinner worked better than Plavix for treating acute coronary syndrome -- but approval isn't a sure thing, due in part to some oddities in the study's results. Continue reading FDA to Decide the Fate of AstraZeneca's Heart Drug Brilinta Thursday FDA to Decide the Fate of AstraZeneca's Heart Drug Brilinta Thursday originally appeared on DailyFinance on Wed, 15 Dec 2010 09:35:00. Filed Under: Company News , Health Care , Bristol-Myers Squibb , Sanofi Aventis , Eli Lilly , Astrazeneca , Stocks in the News Permalink | Tweet this! | Comments
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here